MedTrace Logo

Benefit of GnRH Agonist Before Frozen Embryo Transfer in Patients With Endometriosis and/or Adenomyosis

NCT04356664 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2026-01-16

No results posted yet for this study

Summary

Women suffering from endometriosis and/or adenomyosis may also suffer from infertility. GnRH agonist injection could improve implantation and therefore increase the pregnancy rate in these patients. This study was designed to evaluate effects of the additional of GnRH agonist (single or 2 doses) to the routine oestrogens and progestins use as support before Frozen Embryon Transfer as compared to oestrogens and progestins only.

Conditions

  • Endometriosis
  • Adenomyosis
  • Infertility, Female

Interventions

DRUG

GnRH agonist

One or two intramuscular injections of Decapeptyl 3 mg

Sponsors & Collaborators

  • Hopital Foch

    lead OTHER

Principal Investigators

  • Paul Pirtea, Dr · Hopital Foch

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
36 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-18
Primary Completion
2026-06-18
Completion
2026-06-18

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04356664 on ClinicalTrials.gov